Provision of Assay Kits for SCID Evaluation: EONIS-Q

his request is for re-procurement same scope for 18 months, via a compliant Direct Ward National framework for the EONIS Q Assay methodology, as part of the delivery and implementation of the ongoing NHS Newborn Blood Spot for Severe Combined Immuno-Deficiency (SCID) in-service evaluation (ISE) in 4 Screening laboratories.